Loading
Ascelia Pharma AB Stock: price and insider trades · Sweden
1 insider bought €3,208 of shares over the last 90 days, the latest filed 25 Sept 2026.
Ascelia Pharma AB: what insiders have been doing
This page follows insider dealings at Ascelia Pharma AB as filed with Finansinspektionen, a company from the Health Care sector based in Malmö, Sweden. Between 18 October 2025 and 18 October 2026, 2 insiders published 4 filings.
The flow runs one way only: 1 insider bought (2 purchases totalling €3,208) and nobody sold on the market. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. One trade stands out by size: a purchase of €1,820 from Andreas Linderoth Norlin, disclosed on 25 September 2026, or 0.024% of market capitalisation.
The last insider purchase was made public on 25 September 2026, 22 days ago. Typically, a trade is published a median of 1 day after it takes place. The regulation allows three business days to notify a trade (MAR article 19).
For context, the typical company on the same exchange (median of 890 companies) published 7 filings over the same period, against 4 filings here. Our records for Ascelia Pharma AB go back to 2021, with 3 purchases and no sales on the open market in total.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.
Key facts
Headquarters: Malmö, Sweden
Source: Wikidata (CC0).
Insider Decl.
11
Thresholds
n/a
Buy Volume
€8,047
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleAndreas Linderoth Norlin2 buys
Peter Benson1 buy
Analyst consensus: bullish or bearish?
Analysts rate Ascelia Pharma AB Strong Buy (bullish), based on 3 analysts. Average price target: SEK 1.95.
Financial data
as of FY 2025FY ended December 2025 · cache
SEK 0.56
Analyst consensus
3 analystsStrong buy
SEK 1.00Target SEK 1.95(+247%)SEK 3.70
Income statement
EBITDA-SEK 75M
Net income-SEK 76.3M0.0% margin
Valuation
PER (forward)37.5x
P/Book0.8x
Beta0.77
Balance sheet & cash
Market capSEK 75M
Total debtSEK 970k
Free Cash Flow-SEK 72.3M
Debt / Equity1%
Profitability & ownership
ROE-65.5%
ROA-32.9%
% insiders13.3%
% institutions21.7%
Last declaration on 25 September 2026
Declarations11 total
25,000 shares@ SEK 0.630.018% mcap43.3% of flowAktieISIN SE0010573113FI:csv-b9b9cc5df1990edce020
Canonical exit: 24 Dec 2026 (T+90)
32,519 shares@ SEK 0.6350.024% mcap56.7% of flowAktieISIN SE0010573113FI:csv-dd11d76dc39fbe220541
Canonical exit: 24 Dec 2026 (T+90)
24,975 shares0AktieISIN SE0010573113FI:A003U165-1
1,754 shares0AktieISIN SE0010573113FI:A003U157-1
15,000 shares@ SEK 3.560.070% mcap47.4% of flowAktieISIN SE0010573113FI:A003S559-1
Canonical exit: 22 Dec 2025 (T+90)
6,152 shares@ SEK 2.150.017% mcap11.6% of flowAktieISIN SE0010573113FI:A003N440-1
21,688 shares@ SEK 2.150.060% mcap41.0% of flowWarrantISIN SE0022725438FI:A003N439-1
10,000 shares@ SEK 2.150.028% mcap100.0% of flowAktieISIN SE0010573113FI:A003N414-1
100,000 shares@ SEK 2.150.28% mcap100.0% of flowAktieISIN SE0010573113FI:A003N410-1
112,500 shares0AktieISIN SE0010573113FI:A001P652-2
539,685 shares0AktieISIN SE0010573113FI:A001P626-2
11 of 11 declarations
About Ascelia Pharma AB
Ascelia Pharma AB is a biopharmaceutical company focused on developing treatments for health-related diseases. It is listed on the Stockholm Stock Exchange (XSTO).
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
